Objective: Promoter hypermethylation is emerging as a promising molecular strategy for early detection of cancer. We examined promoter methylation status of 1143 cancer-associated genes to perform a global but unbiased inspection of methylated regions in head and neck squamous cell carcinoma (HNSCC).
Study Design: Laboratory-based study.
Setting: Integrated health care system.
Subjects and Methods: Five samples, two frozen primary HNSCC biopsies and three HNSCC cell lines, were examined. Whole genomic DNA was interrogated using a combination of DNA immunoprecipitation (IP) and Affymetrix whole-genome tiling arrays.
Results: Of the 1143 unique cancer genes on the array, 265 were recorded across five samples. Of the 265 genes, 55 were present in all five samples, and 36 were common to four of five samples, 46 to three of five, 56 to two of five, and 72 to one of five samples. Hypermethylated genes in the five samples were cross-examined against those in PubMeth, a cancer methylation database combining text mining and expert annotation (http://www.pubmeth.org). Of the 441 genes in PubMeth, only 33 are referenced to HNSCC. We matched 34 genes in our samples to the 441 genes in the PubMeth database. Of the 34 genes, eight are reported in PubMeth as HNSCC associated.
Conclusion: This pilot study examined the contribution of global DNA hypermethylation to the pathogenesis of HNSCC. The whole-genome methylation approach indicated 231 new genes with methylated promoter regions not yet reported in HNSCC. Examination of this comprehensive gene panel in a larger HNSCC cohort should advance selection of HNSCC-specific candidate genes for further validation as biomarkers in HNSCC.
Get full access to this article
View all access options for this article.
References
1.
CostelloJFPlassC.Methylation matters. J Med Genet2001; 38:285–303.
2.
LiEBeardCJaenischR.Role for DNA methylation in genomic imprinting. Nature1993; 366:362–5.
3.
PfeiferGPTanguayRLSteigerwaldSDIn vivo footprint and methylation analysis by PCR-aided genomic sequencing: comparison of active and inactive X chromosomal DNA at the CpG island and promoter of human PGK-1. Genes Dev1990; 4:1277–87.
4.
CostelloJFFruhwaldMCSmiragliaDJAberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet2000; 24:132–8.
5.
SmiragliaDJSmithLTLangJCDifferential targets of CpG island hypermethylation in primary and metastatic head and neck squamous cell carcinoma (HNSCC). J Med Genet2003; 40:25–33.
6.
JonesPALairdPW.Cancer epigenetics comes of age. Nat Genet1999; 21:163–7.
7.
CairnsP.Detection of promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Ann N Y Acad Sci2004; 1022:40–3.
8.
WorshamMJPalsGSchoutenJPDelineating genetic pathways of disease progression in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg2003; 129:702–8.
9.
WorshamMJChenKMTiwariNFine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg2006; 132:409–15.
10.
Sanchez-CespedesMOkamiKCairnsPMolecular analysis of the candidate tumor suppressor gene ING1 in human head and neck tumors with 13q deletions. Genes Chromosomes Cancer2000; 27:319–22.
11.
MaruyaSIssaJPWeberRSDifferential methylation status of tumor-associated genes in head and neck squamous carcinoma: incidence and potential implications. Clin Cancer Res2004; 10:3825–30.
12.
WorshamMJChenKMMeduriVEpigenetic events of disease progression in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg2006; 132:668–77.
13.
WorshamMJWolmanSRCareyTEChromosomal aberrations identified in culture of squamous carcinomas are confirmed by fluorescence in situ hybridisation. Mol Pathol1999; 52:42–6.
14.
OngenaertMVan NesteLDe MeyerTPubMeth: a cancer methylation database combining text-mining and expert annotation. Nucleic Acids Res2008; 36:D842–6.
15.
JemalASiegelRWardECancer statistics, 2009. CA Cancer J Clin2009; 59:225–49.
16.
EdwardsBKBrownMLWingoPAAnnual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst2005; 97:1407–27.
17.
EstellerMCornPGBaylinSBA gene hypermethylation profile of human cancer. Cancer Res2001; 61:3225–9.
18.
ChenKSawhneyRKhanMMethylation of multiple genes as diagnostic and therapeutic markers in primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg2007; 133: 1131–8.
19.
PeggAE.Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res1990; 50:6119–29.
20.
HirohashiS.Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol1998; 153:333–9.
21.
StephenJKVaughtLEChenKMEpigenetic events underlie the pathogenesis of sinonasal papillomas. Mod Pathol2007; 20: 1019–27.
22.
StephenJKVaughtLEChenKMAn epigenetically derived monoclonal origin for recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg2007; 133:684–92.
23.
FlissMSUsadelHCaballeroOLFacile detection of mito-chondrial DNA mutations in tumors and bodily fluids. Science2000; 287:2017–9.
24.
Sanchez-CespedesMEstellerMWuLGene promoter hyper-methylation in tumors and serum of head and neck cancer patients. Cancer Res2000; 60:892–5.
